Increased risk of cognitive impairment in patients with diabetes is associated with metformin

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 2981-2987

  Moore, Eileen M ^a,b   Mander, Alastair G ^b   Ames, David ^a,c   Kotowicz, Mark A ^a,b,d   Carne, Ross P ^b,d   Brodaty, Henry ^e,f   Woodward, Michael ^g   Boundy, Karyn ^h   Ellis, Kathryn A ^a,c   Bush, Ashley I ^a   Faux, Noel G ^a   Martins, Ralph ^i,j   Szoeke, Cassandra ^c,k   Rowe, Christopher ^l   Watters, David A ^b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BARWON HEALTH   (Australia)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^h QUEEN ELIZABETH HOSPITAL   (Australia)

ⁱ EDITH COWAN UNIVERSITY   (Australia)

^j HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^k CSIRO   (Australia)

^l AUSTIN HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYANOCOBALAMIN; METFORMIN;

ACADEMIC ACHIEVEMENT; ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEPRESSION; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; SEX DIFFERENCE; SUPPLEMENTATION; VERY ELDERLY; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CALCIUM; COGNITION DISORDERS; DIABETES MELLITUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 84890094663     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0229     Document Type: Article

References (40)

1. Gonz-alez EL, Johansson S, WallanderMA, Rodr-?guez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996- 2005. J Epidemiol Community Health 2009;63:332-336
2. Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, Nobili A, et al. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian populationbased study. Diabet Med 2012;29:385-392
3. Boyle JP, Thompson TJ,Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8: 29-41
4. Zhang YH, Ma WJ, Thomas GN, et al. Diabetes and pre-diabetes as determined by glycated haemoglobin A1c and glucose levels in a developing southern Chinese population. PLoS One 2012;7:e37260
5. Maga A, de Courten M, Dan L, et al. American Samoa NCD Risk Factors STEPS Report. Suva, Fiji, Department of Health, World Health Organization, 2007
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia withmacrovascular andmicrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
7. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329:977-986
9. Ravona-Springer R, Luo X, Schmeidler J, et al. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord 2010;29:68-74
10. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2009;67:505-512
11. Zhou G, Myers R, Li Y, et al. Role of AMPactivated protein kinase in mechanism of metformin action. J Clin Invest 2001;108: 1167-1174
12. HuizingaMM, Roumie CL, Elasy TA, et al. Changing incident diabetes regimens: a Veterans Administration cohort study from 2000 to 2005. Diabetes Care 2007; 30:e85
13. Proust-Lima C, Amieva H, Dartigues JF, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol 2007;165:344-350
14. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. BMJ 1971;2:685-687
15. Andrès E, Vidal-Alaball J, Federici L, Loukili NH, Zimmer J, Kaltenbach G. Clinical aspects of cobalamin deficiency in elderly patients. Epidemiology, causes, clinical manifestations, and treatment with special focus on oral cobalamin therapy. Eur J Intern Med 2007;18:456-462
16. Stowers JM, Smith OA. Vitamin B 12 and metformin. BMJ 1971;3:246-247
17. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340: c2181-c2187
18. Wile DJ, Toth C. Association ofmetformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010;33:156-161
19. BaumanWA, ShawS, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced bymetformin. Diabetes Care 2000; 23:1227-1231
20. Oliveira AM, BadingH. Calciumsignaling in cognition and aging-dependent cognitive decline. Biofactors 2011;37:168-174
21. Chen Y, Zhou K, Wang R, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 2009; 106:3907-3912
22. Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a populationbased case-control study. J Am Geriatr Soc 2012;60:916-921
23. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistantmice. Pharmacol Biochem Behav 2012;101:564-574
24. Wang J, Gallagher D, DeVito LM, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012;11:23-35
25. Hsu CC,Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011;24:485-493
26. Brodaty H, Woodward M, Boundy K, Ames D, Balshaw R; PRIME Study Group Patients in Australian Memory Clinics: baseline characteristics and predictors of decline at six months. Int Psychogeriatr 2011;23:1086-1096
27. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009;21:672-687
28. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269: 2386-2391
29. Iverson GL. Interpretation of Mini-Mental State Examination scores in communitydwelling elderly and geriatric neuropsychiatry patients. Int J Geriatr Psychiatry 1998;13:661-666
30. Colagiuri S,Dickinson S,Girgis S,Colagiuri R. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Canberra, Diabetes Australia and the NHMRC, 2009
31. Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in theHeidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98: 920-925
32. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341: c3691-c3699
33. Bollanc MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of theWomen's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040-d2048
34. West SL, Swan VJ, Jamal SA. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clin J Am Soc Nephrol 2010; 5(Suppl. 1):S41-S47
35. Rejnmark L, Avenell A, Masud T, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 2012;97:2670-2681
36. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S14-S21
37. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease. JOP 2005;6:287-302
38. Moore E, Mander A, Ames D, Carne R, Sanders K, Watters D. Cognitive impairment and vitamin B12: a review. Int Psychogeriatr 2012;24:1-16
39. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36:431-441
40. Ames D, Flynn E. Dementia services: an Australian view. In Dementia. Burns A, Levy R, Eds. London, Chapman and Hall Medical, 1994, p. 611-621